| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP2K6 |
| Uniprot No | P52564 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-334aa |
| 氨基酸序列 | MSQSKGKKRNPGLKIPKEAFEQPQTSSTPPRDLDSKACISIGNQNFEVKA DDLEPIMELGRGAYGVVEKMRHVPSGQIMAVKRIRATVNSQEQKRLLMDL DISMRTVDCPFTVTFYGALFREGDVWICMELMDTSLDKFYKQVIDKGQTI PEDILGKIAVSIVKALEHLHSKLSVIHRDVKPSNVLINALGQVKMCDFGI SGYLVDSVAKTIDAGCKPYMAPERINPELNQKGYSVKSDIWSLGITMIEL AILRFPYDSWGTPFQQLKQVVEEPSPQLPADKFSAEFVDFTSQCLKKNSK ERPTYPELMQHPFFTLHESKGTDVASFVKLILGD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP2K6重组蛋白的参考文献示例(内容为虚构，仅作格式参考)：
1. **文献名称**：《重组MAP2K6蛋白在大肠杆菌中的高效表达与功能鉴定》
**作者**：Chen L, Wang Y, et al.
**摘要**：研究通过大肠杆菌表达系统成功制备了高纯度重组MAP2K6蛋白，并验证其通过磷酸化下游p38 MAPK的活性，为体外激酶研究提供工具。
2. **文献名称**：《MAP2K6结构与激活机制的体外重构分析》
**作者**：Kim S, Tanaka H, et al.
**摘要**：利用重组MAP2K6蛋白进行晶体结构解析，揭示了其与MKK3的相互作用位点及在氧化应激信号通路中的激活机制。
3. **文献名称**：《MAP2K6重组蛋白在肝癌细胞凋亡中的功能研究》
**作者**：Zhang R, Liu X, et al.
**摘要**：通过体外实验证明，重组MAP2K6可增强TNF-α诱导的肝癌细胞凋亡，提示其在癌症治疗中的潜在靶点作用。
4. **文献名称**：《基于昆虫表达系统的MAP2K6重组蛋白生产及药物筛选应用》
**作者**：Gupta P, et al.
**摘要**：采用杆状病毒-昆虫细胞系统表达功能性MAP2K6蛋白，并建立高通量筛选平台以发现其小分子抑制剂。
建议通过PubMed、Web of Science或Google Scholar检索真实文献，关键词为“MAP2K6 recombinant protein”或“MEK6 expression”。
**Background of MAP2K6 Recombinant Protein**
MAP2K6 (Mitogen-Activated Protein Kinase Kinase 6), also known as MEK6 or MKK6. is a dual-specificity serine/threonine kinase that plays a critical role in the MAPK (Mitogen-Activated Protein Kinase) signaling cascade. It functions downstream of MAP3Ks (e.g., ASK1. TAOK1) and directly phosphorylates and activates p38 MAPK (MAPK14), a key regulator of cellular responses to stress, inflammation, apoptosis, and differentiation. MAP2K6 is activated by pro-inflammatory cytokines, environmental stressors, and growth factors, making it pivotal in pathways linked to immune regulation, cancer progression, and neurodegenerative diseases.
Recombinant MAP2K6 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. The purified protein retains kinase activity, enabling researchers to study its enzymatic mechanisms, substrate interactions, and regulatory roles *in vitro*. It is commonly utilized in kinase assays, drug discovery (e.g., screening p38 pathway inhibitors), and structural studies to elucidate its activation loop dynamics or binding interfaces.
Dysregulation of MAP2K6-p38 signaling is implicated in pathologies such as rheumatoid arthritis, Alzheimer’s disease, and certain cancers. Recombinant MAP2K6 facilitates the development of targeted therapies by serving as a tool to validate inhibitors or modulators. Its high purity and activity are ensured via affinity tags (e.g., His-tag) and quality control assays (e.g., SDS-PAGE, Western blot, kinase activity tests). Overall, MAP2K6 recombinant protein is indispensable for dissecting stress-responsive pathways and advancing translational research.
×
